Article
Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Trial-Based Economic Evaluation.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 1 Nov 2025
Ter Hark Sophie E, Kievit Wietske, Hannink Gerjon, Vos Cornelis F, Spijker Jan, van der Meij Annemarie, Grotenhuis Anne J, Mihaescu Raluca, Donders Rogier, Aarnoutse Rob E, Schellekens Arnt F A, Coenen Marieke J H, Janzing Joost G E
Abstract excerpt
OBJECTIVES: To evaluate the cost-effectiveness of preemptive CYP2D6 and CYP2C19 genotype-informed tricyclic antidepressant dosing from a societal and a healthcare perspective. METHODS: A trial-based cost-effectiveness analysis was conducted with data from the Pharmacogenetics for Individualized Tricyclic Antidepressant dosing study. This multicenter randomized controlled trial (n = 111) compared...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
